Wednesday, July 27, 2022 Daily Archives

Ginkgo forks out $300m to acquire Zymergen

Through the acquisition of Zymergen, Ginkgo Bioworks anticipates accelerating the development of its horizontal synthetic biology platform. According to Gingko, the $300 million deal will see it implement Zymergen’s software, data science tools, automation, and biological assets into its business. In turn, Ginkgo expects this to increasingly enhance the capacity, efficiency, and capabilities of its platform. Ginkgo describes itself as “a horizontal platform, serving customers across industries rather than producing its own products.” This acquisition will see the firm support…

Lonza H1: Biologics biz boosted by $130m Allakos cancellation fee

Capacity cancellations are both common and ‘integral’ in the CDMO space says Lonza, as it reports a $130 million termination fee as a one-time item in its first half 2022 financials. For the first half 2022, contract development and manufacturing organization (CDMO) Lonza reported sales within its biologics division of CHF 1.63 billion ($1.68 billion), up 26% on the year prior. The company attributed this to sustained demand across end markets, supported by capacity expansions ramp-ups, but the period was…

TFBS to grow viral vector ops with help from Univercells

TFBS Biosciences’ will use Univercells Technologies scale-X platform at its facility in Taipei City to expand its viral vector operations. Contract development manufacturing organization (CDMO) TFBS claims it is the first viral vector production provider in Taiwan and plans to use Univercells’ scale-X carbo mid-scale fixed-bed bioreactor to expand its viral vector operations. “Univercells Technologies will provide a range of integrated services to the TFBS team, levering our understanding of the technology and its application for many processes. The main…